PRODH2

Across TCGA cell cohorts, PRODH2 mutation is significantly associated with the drug of many other genes, with 47 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible PRODH2-associated genes across cancer lineages are Ruxolitinib, FY069, and N22899-6-C1. Each is linked with PRODH2 in more than 1 cancer types. Because this analysis shows association rather than direction, both PRODH2-to-partner and partner-to-PRODH2 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Ruxolitinib grouped by PRODH2-low versus PRODH2-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (PRODH2→partner) and Y-score (partner→PRODH2) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Ruxolitinib →	+0.342	+2.646	.025	.047	3	2
LARGE_INTESTINE	FY069 →	+0.408	+2.649	.035	.046	3	1
LARGE_INTESTINE	N22899-6-C1 →	+0.228	+2.777	.030	.030	3	1
LARGE_INTESTINE	PLK_6522 →	+1.008	+2.710	.001	.027	3	1
LARGE_INTESTINE	GSK2801 →	+0.409	+2.649	.009	.046	3	1
LARGE_INTESTINE	LMB_AB3 →	+0.360	+2.649	.044	.046	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 47 associations by consensus.

Ruxolitinib by PRODH2 expression — LARGE_INTESTINE

Explore this box plot interactively →